Victoza (liraglutide) is in a class of diabetes drugs called incretin mimetics or GLP-1 mimetics.
It is taken once-a-day by injection in the thigh, upper arm, or stomach.
Along with diet and exercise, Victoza works to control blood sugar levels for individuals diagnosed with type-2 diabetes.
It was approved by the FDA in January 2010.
This class of drug works by mimicking an incretin which is a natural hormone that boosts insulin production and regulates blood-sugar levels in the pancreas.
This boost is very important for diabetics in order to keep sugar from building up in the bloodstream.
Other incretin mimetic drugs in the same class are Byetta, Byuderon, Januvia, and Janumet.
Studies have revealed a concern that incretin mimetics may actually increase the risk of pancreatitis and over time pancreatitis is known to increase the risk of pancreatic cancer.
In May 2013, the FDA issued a safety communication linking incretin mimetics to pancreatic disease.
They told the public they were investigating the drug’s link to pancreatic cancer.